Treatment of multiple sclerosis using pkc activators

Abstract

A method for treating or preventing mild, moderate, or advanced multiple sclerosis (MS) in a subject, the method comprising administering to the subject a PKC activating compound (e.g., a bryostatin, such as bryostatin-1, or a bryolog) in a therapeutically effective amount to result in mitigation or prevention of demyelination, initiation of remyelination, or reduction or prevention of neuroinflammation in early MS. The MS may be, for example, relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), or progressive-relapsing MS (PRMS). The PKC activating compound may be administered at an initial loading dose of about 15, 24, or 48 micrograms weekly in the first one week or consecutive two or three weeks, followed by doses of about 12, 20, or 40 micrograms alternately every two or three weeks for at least 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, or 30 total weeks.

Dependencies are inferred from the claim text.